{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:42:37Z","timestamp":1789123357853,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03771-5","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:42:10Z","timestamp":1789116130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antihypertensive Medication Patterns in Patients with Hypertension that is Harder to Control: Insights from the EnligHTN Study"],"prefix":"10.1007","author":[{"given":"Jesper N.","family":"Bech","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi R.","family":"Ben Dor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Hougaard Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina T.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Erhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty M.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Coto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"38","key":"3771_CR1","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"issue":"12","key":"3771_CR2","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"10258","key":"3771_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","unstructured":"GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1223\u201349.","journal-title":"Lancet"},{"issue":"33","key":"3771_CR4","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"6","key":"3771_CR5","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, et al. International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334\u201357.","journal-title":"Hypertension"},{"issue":"10","key":"3771_CR6","first-page":"e212","volume":"82","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212\u2013316.","journal-title":"Hypertension"},{"issue":"10313","key":"3771_CR7","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","volume":"398","author":"M Nazarzadeh","year":"2021","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type\u00a02 diabetes: an individual participant data meta-analysis. Lancet. 2021;398(10313):1803\u201310.","journal-title":"Lancet"},{"issue":"9","key":"3771_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","volume":"10","author":"M Nazarzadeh","year":"2022","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type\u00a02 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol. 2022;10(9):645\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10285","key":"3771_CR9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625\u201336.","journal-title":"Lancet"},{"issue":"10305","key":"3771_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021;398(10305):1053\u201364.","journal-title":"Lancet"},{"issue":"1","key":"3771_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12882-020-02151-7","volume":"21","author":"M Weldegiorgis","year":"2020","unstructured":"Weldegiorgis M, Woodward M. The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis. BMC Nephrol. 2020;21(1):506.","journal-title":"BMC Nephrol"},{"issue":"10022","key":"3771_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957\u201367.","journal-title":"Lancet"},{"issue":"10304","key":"3771_CR13","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"NCD Risk Factor Collaboration","year":"2021","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104\u00a0million participants. Lancet. 2021;398(10304):957\u201380.","journal-title":"Lancet"},{"issue":"2","key":"3771_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/cvr\/cvac130","volume":"119","author":"AE Schutte","year":"2023","unstructured":"Schutte AE, Jafar TH, Poulter NR, et al. Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. Cardiovasc Res. 2023;119(2):381\u2013409.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"3771_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-04109-1","volume":"24","author":"YL Niriayo","year":"2024","unstructured":"Niriayo YL, Girmay S, Tesfay N, Gidey K, Asgedom SW. Therapeutic inertia and contributing factors among ambulatory patients with hypertension. BMC Cardiovasc Disord. 2024;24(1):523.","journal-title":"BMC Cardiovasc Disord"},{"issue":"10","key":"3771_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/jch.14699","volume":"25","author":"C Darricarrere","year":"2023","unstructured":"Darricarrere C, Jacquot E, Bricout S, Louis C, B\u00e9nard M, Poulter NR. Uncontrolled blood pressure and therapeutic inertia in treated hypertensive patients: a retrospective cohort study using a UK general practice database. J Clin Hypertens (Greenwich). 2023;25(10):895\u2013904.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"3771_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/jhh.2014.73","volume":"29","author":"DJ Hyman","year":"2015","unstructured":"Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. J Hum Hypertens. 2015;29(4):213\u20138.","journal-title":"J Hum Hypertens"},{"issue":"12","key":"3771_CR18","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1097\/HJH.0000000000001502","volume":"35","author":"H Durand","year":"2017","unstructured":"Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35(12):2346\u201357.","journal-title":"J Hypertens"},{"issue":"4","key":"3771_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005641","volume":"96","author":"TM Abegaz","year":"2017","unstructured":"Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e5641.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"3771_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034787","volume":"14","author":"JT Mohl","year":"2025","unstructured":"Mohl JT, Moreno CA, Sadik K, Singhal M, Rooney A, Ciemins EL. Evaluation of blood pressure control, medication adherence, and therapeutic inertia in US patients with hypertension prescribed multiple antihypertensives. J Am Heart Assoc. 2025;14(12):e034787.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"3771_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYP.0000000000000203","volume":"79","author":"NK Choudhry","year":"2022","unstructured":"Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension. 2022;79(1):e1\u201314.","journal-title":"Hypertension"},{"key":"3771_CR22","doi-asserted-by":"publisher","first-page":"1564791","DOI":"10.3389\/fmed.2025.1564791","volume":"12","author":"HJ Kim","year":"2025","unstructured":"Kim HJ, Kim BS, Kim H, Lee J, Shin JH, Sung KC. Impact of blood pressure and medication adherence on clinical outcomes in patients with hypertension. Front Med (Lausanne). 2025;12:1564791.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3771_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12889-025-21409-z","volume":"25","author":"A Hossain","year":"2025","unstructured":"Hossain A, Ahsan GU, Hossain MZ, et al. Medication adherence and blood pressure control in treated hypertensive patients: first follow-up findings from the PREDIcT-HTN study in Northern Bangladesh. BMC Public Health. 2025;25(1):250.","journal-title":"BMC Public Health"},{"issue":"3","key":"3771_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.ajkd.2023.09.009","volume":"83","author":"JB Cohen","year":"2024","unstructured":"Cohen JB, Bress AP. Entering a new era of antihypertensive therapy. Am J Kidney Dis. 2024;83(3):411\u20134.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"3771_CR25","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53\u201390.","journal-title":"Hypertension"},{"issue":"7","key":"3771_CR26","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s11739-023-03376-8","volume":"18","author":"S Romano","year":"2023","unstructured":"Romano S, Rigon G, Albrigi M, et al. Hypertension, uncontrolled hypertension and resistant hypertension: prevalence, comorbidities and prescribed medications in 228,406 adults resident in urban areas. A population-based observational study. Intern Emerg Med. 2023;18(7):1951\u20139.","journal-title":"Intern Emerg Med"},{"issue":"1","key":"3771_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27377-2","volume":"8","author":"D Zhou","year":"2018","unstructured":"Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHANES III Linked Mortality Study. Sci Rep. 2018;8(1):9418.","journal-title":"Sci Rep"},{"issue":"1","key":"3771_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jash.2010.02.002","volume":"4","author":"AS Iyer","year":"2010","unstructured":"Iyer AS, Ahmed MI, Filippatos GS, et al. Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. J Am Soc Hypertens. 2010;4(1):22\u201331.","journal-title":"J Am Soc Hypertens"},{"key":"3771_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03681-6","author":"T McCormack","year":"2026","unstructured":"McCormack T, Ben Dor NR, Norris T, et al. Uncontrolled hypertension prevalence, characteristic profiles, and risk of cardiorenal and metabolic outcomes: insights from the EnligHTN study. Adv Ther. 2026. https:\/\/doi.org\/10.1007\/s12325-026-03681-6.","journal-title":"Adv Ther"},{"issue":"8","key":"3771_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.1230","volume":"15","author":"SE Andrade","year":"2006","unstructured":"Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565\u201374 (discussion 75-7).","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"3771_CR31","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.2337\/dc16-1925","volume":"40","author":"K Khunti","year":"2017","unstructured":"Khunti K, Seidu S, Kunutsor S, Davies M. Association between adherence to pharmacotherapy and outcomes in type\u00a02 diabetes: a meta-analysis. Diabetes Care. 2017;40(11):1588\u201396.","journal-title":"Diabetes Care"},{"issue":"12","key":"3771_CR32","doi-asserted-by":"publisher","first-page":"e2247787","DOI":"10.1001\/jamanetworkopen.2022.47787","volume":"5","author":"BM Egan","year":"2022","unstructured":"Egan BM, Sutherland SE, Macri CI, et al. Association of baseline adherence to antihypertensive medications with adherence after shelter-in-place guidance for COVID-19 among US adults. JAMA Netw Open. 2022;5(12):e2247787.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"3771_CR33","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/ajh\/hpae141","volume":"38","author":"ST Hardy","year":"2025","unstructured":"Hardy ST, Jaeger BC, Foti K, Ghazi L, Wozniak G, Muntner P. Trends in blood pressure control among US adults with hypertension, 2013\u20132014 to 2021\u20132023. Am J Hypertens. 2025;38(2):120\u20138.","journal-title":"Am J Hypertens"},{"issue":"10","key":"3771_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004188","volume":"5","author":"L Mu","year":"2016","unstructured":"Mu L, Mukamal KJ. Treatment intensification for hypertension in US ambulatory medical care. J Am Heart Assoc. 2016;5(10):e004188.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"3771_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-018-0802-1","volume":"20","author":"R Josiah Willock","year":"2018","unstructured":"Josiah Willock R, Miller JB, Mohyi M, Abuzaanona A, Muminovic M, Levy PD. Therapeutic inertia and treatment intensification. Curr Hypertens Rep. 2018;20(1):4.","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"3771_CR36","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/HYPERTENSIONAHA.122.19882","volume":"80","author":"N Chiu","year":"2008","unstructured":"Chiu N, Chiu L, Aggarwal R, Raber I, Bhatt DL, Mukamal KJ. Trends in blood pressure treatment intensification in older adults with hypertension in the United States, 2008 to 2018. Hypertension. 2008;80(3):553\u201362.","journal-title":"Hypertension"},{"issue":"25","key":"3771_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011121","volume":"97","author":"T Milman","year":"2018","unstructured":"Milman T, Joundi RA, Alotaibi NM, Saposnik G. Clinical inertia in the pharmacological management of hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(25):e11121.","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"3771_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026582","volume":"11","author":"EKP Lee","year":"2022","unstructured":"Lee EKP, Poon P, Yip BHK, et al. Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27\u00a0million patients. J Am Heart Assoc. 2022;11(17):e026582.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"3771_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","volume":"69","author":"P Gupta","year":"2017","unstructured":"Gupta P, Patel P, \u0160trauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69(6):1113\u201320.","journal-title":"Hypertension"},{"issue":"8","key":"3771_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare9081085","volume":"9","author":"A Gavrilova","year":"2021","unstructured":"Gavrilova A, Bandere D, Logviss K, \u0160mits D, Urt\u0101ne I. Adherence level to arterial hypertension treatment: a cross-sectional patient survey and retrospective analysis of the NHS prescription database. Healthcare (Basel). 2021;9(8):1085.","journal-title":"Healthcare (Basel)"},{"issue":"6","key":"3771_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11606-009-1240-1","volume":"25","author":"JE Bailey","year":"2010","unstructured":"Bailey JE, Wan JY, Tang J, Ghani MA, Cushman WC. Antihypertensive medication adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med. 2010;25(6):495\u2013503.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"3771_CR42","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/HJH.0b013e328342ca97","volume":"29","author":"G Corrao","year":"2011","unstructured":"Corrao G, Parodi A, Nicotra F, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610\u20138.","journal-title":"J Hypertens"},{"issue":"5","key":"3771_CR43","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/MLR.0b013e3181d567bd","volume":"48","author":"A Dragomir","year":"2010","unstructured":"Dragomir A, C\u00f4t\u00e9 R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418\u201325.","journal-title":"Med Care"},{"issue":"16","key":"3771_CR44","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCULATIONAHA.108.830299","volume":"120","author":"G Mazzaglia","year":"2009","unstructured":"Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598\u2013605.","journal-title":"Circulation"},{"issue":"11","key":"3771_CR45","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/jhh.2017.48","volume":"31","author":"DM van der Laan","year":"2017","unstructured":"van der Laan DM, Elders PJM, Boons C, Beckeringh JJ, Nijpels G, Hugtenburg JG. Factors associated with antihypertensive medication non-adherence: a systematic review. J Hum Hypertens. 2017;31(11):687\u201394.","journal-title":"J Hum Hypertens"},{"key":"3771_CR46","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2147\/PPA.S457026","volume":"18","author":"RI Farah","year":"2024","unstructured":"Farah RI, Alawwa IA, Khateeb DQ, et al. Factors affecting the level of adherence to hypertension medications: a cross-sectional study using the hill-bone questionnaire. Patient Prefer Adherence. 2024;18:893\u2013904.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"3771_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0305941","volume":"19","author":"S Sharma","year":"2024","unstructured":"Sharma S, Sharma CR, Sharma S, Aryal S, Bhandari B. Adherence to antihypertensive medication and its associated factors among patients with hypertension attending a tertiary hospital in Kathmandu, Nepal. PLoS One. 2024;19(7):e0305941.","journal-title":"PLoS One"},{"issue":"11","key":"3771_CR48","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.sapharm.2024.07.006","volume":"20","author":"P Zare","year":"2024","unstructured":"Zare P, Poustchi H, Mohammadi Z, et al. Polypharmacy and medication usage patterns in hypertensive patients: findings from the Pars Cohort Study. Res Social Adm Pharm. 2024;20(11):1038\u201346.","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"3771_CR49","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","volume":"29","author":"SL Samson","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: comprehensive type\u00a02 diabetes management algorithm - 2023 update. Endocr Pract. 2023;29(5):305\u201340.","journal-title":"Endocr Pract"},{"issue":"4s","key":"3771_CR50","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4s):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"18","key":"3771_CR51","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"1","key":"3771_CR52","doi-asserted-by":"publisher","first-page":"18764","DOI":"10.1038\/s41598-023-44813-0","volume":"13","author":"E Ji","year":"2023","unstructured":"Ji E, Ahn S, Choi JY, Kim CH, Kim KI. Effect of multimorbidity on hypertension management. Sci Rep. 2023;13(1):18764.","journal-title":"Sci Rep"},{"issue":"6","key":"3771_CR53","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1161\/HYPERTENSIONAHA.124.24316","volume":"82","author":"A Kumar","year":"2025","unstructured":"Kumar A, Therrien NL, Ogwuegbu JI, et al. Blood pressure-elevating and antihypertensive medication prescription trends. Hypertension. 2025;82(6):1106\u201315.","journal-title":"Hypertension"},{"issue":"23","key":"3771_CR54","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/eurheartj\/ehac395","volume":"44","author":"L Lauder","year":"2023","unstructured":"Lauder L, Mahfoud F, Azizi M, et al. Hypertension management in patients with cardiovascular comorbidities. Eur Heart J. 2023;44(23):2066\u201377.","journal-title":"Eur Heart J"},{"key":"3771_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12875-015-0313-y","volume":"16","author":"C Sarkar","year":"2015","unstructured":"Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a cross-sectional study of the role of multimorbidity in blood pressure control. BMC Fam Pract. 2015;16:98.","journal-title":"BMC Fam Pract"},{"issue":"1","key":"3771_CR56","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.004531","volume":"2","author":"MS Paulsen","year":"2012","unstructured":"Paulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and blood pressure control in 37 651\u00a0hypertensive patients from Danish general practice. J Am Heart Assoc. 2012;2(1):e004531.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"3771_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2020-001461","volume":"8","author":"N Tapela","year":"2021","unstructured":"Tapela N, Collister J, Clifton L, Turnbull I, Rahimi K, Hunter DJ. Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK. Open Heart. 2021;8(1):e001461.","journal-title":"Open Heart"},{"issue":"1","key":"3771_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ahj.2013.09.014","volume":"167","author":"NK Choudhry","year":"2014","unstructured":"Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J. 2014;167(1):51-8.e5.","journal-title":"Am Heart J"},{"issue":"4","key":"3771_CR59","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MLR.0000000000000328","volume":"53","author":"JA Schmittdiel","year":"2015","unstructured":"Schmittdiel JA, Nichols GA, Dyer W, Steiner JF, Karter AJ, Raebel MA. Health care system-level factors associated with performance on Medicare STAR adherence metrics in a large, integrated delivery system. Med Care. 2015;53(4):332\u20137.","journal-title":"Med Care"},{"key":"3771_CR60","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jsat.2015.05.002","volume":"57","author":"AL McRae-Clark","year":"2015","unstructured":"McRae-Clark AL, Baker NL, Sonne SC, DeVane CL, Wagner A, Norton J. Concordance of direct and indirect measures of medication adherence in a treatment trial for cannabis dependence. J Subst Abuse Treat. 2015;57:70\u20134.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"3771_CR61","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00115677-200715020-00006","volume":"15","author":"J Hawkshead","year":"2007","unstructured":"Hawkshead J, Krousel-Wood MA. Techniques for measuring medication adherence in hypertensive patients in outpatient settings. Dis Manag Health Out. 2007;15(2):109\u201318.","journal-title":"Dis Manag Health Out"},{"issue":"19","key":"3771_CR62","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027099","volume":"11","author":"D Osula","year":"2022","unstructured":"Osula D, Wu B, Schesing K, et al. Comparison of pharmacy refill data with chemical adherence testing in assessing medication nonadherence in a safety net hospital setting. J Am Heart Assoc. 2022;11(19):e027099.","journal-title":"J Am Heart Assoc"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03771-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:02:28Z","timestamp":1789120948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03771-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":62,"alternative-id":["3771"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03771-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jesper N. Bech declares consulting fees: AstraZeneca; participation in advisory councils or committees: AG, AstraZeneca, and Bayer. Terry McCormack declares consulting\/speaker fees: AstraZeneca, Daiichi Sankyo, Medtronic, and Novartis. Vivek Bhalla declares grants\/consulting fees: AHA, Idorsia, Medtronic, and NIH; participation in advisory councils or committees: AHA, AMA, AstraZeneca, Bayer, Idorsia, and Medtronic; stock\/shares: Nephrogen and Pyrames. Naomi R. Ben Dor declares consulting fees: AstraZeneca. Julian Segura declares consulting\/speaker fees: AstraZeneca, Bayer, Menarini, MSD, Novartis, Novo Nordisk, Servier, and Vifor. S\u00f8ren Hougaard Christiansen and Ina T. Andersen declare no personal conflict of interest. The present study was funded by a grant from AstraZeneca to Aarhus University. The Department of Clinical Epidemiology is involved in other studies with funding from various companies as research grants to (and administered by) Aarhus University. Clement Erhard, Kirsty M. Rhodes, Tom Norris, and Esteban Coto declare employment at the time of the study: AstraZeneca; stock\/shares: AstraZeneca. Kirsty M. Rhodes is a current employee of GlaxoSmithKline and declares stock\/shares. Joachim Weil declares consulting fees: AstraZeneca, Daiichi Sankyo, and Novartis; participation in advisory councils or committees: Medtronic and ReCor.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The EnligHTN study was conducted in accordance with the Declaration of Helsinki, International Conference on Harmonization of Good Clinical Practice, and applicable legislation on non-interventional and\/or observational studies. The protocol for this study was approved by CPRD (protocol number 24_004211). Ethical approval was also provided by the ethics committee of San Carlos Clinic Hospital (Madrid, Spain; approval ID: 24\/545-O-M_NoSP) and the Meuhedet Health Organization (Israel; approval ID: 0025\u201324-MEU). In the other participating countries, ethical approval was not required. Disease Analyzer (Germany) includes only anonymized data in compliance with the regulations of the applicable data protection laws. German law allows the use of anonymous EMR for research purposes. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data. Because patients were only queried as aggregates and no protected health information was available for queries, no institutional review board approval was required for the use of this database or the completion of this study. Use of IQVIA Ambulatory EMR-US linked with IQVIA PharMetrics\u00ae Plus Closed Health Plan claims (USA) is permitted under US law when data are de-identified and used under contractual and privacy safeguards. PharMetrics Plus contains HIPAA-compliant, de-identified claims. Once data are de-identified per HIPAA\u2019s Safe Harbor or Expert Determination standards, HIPAA no longer requires individual authorization (consent) for secondary use and disclosure. IQVIA licenses these data to users under data use agreements that restrict re-identification and regulate use. Informed consent to use these de-identified data was not required. According to Danish law, no ethical committee approval is needed for registry-based non-interventional studies like EnligHTN. The study is covered by Aarhus University\u2019s institutional registration according to the General Data Protection Regulation. Permission to analyze and publish these data was received by each database owner.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}